Interestingly, hypoxic ERBB2-expressing cells in 3D culture were hypersensitive to trametinib treatment alone compared to normoxic cells, suggesting that hypoxic cancer cells may be more dependent on the MEK-ERK pathway for cell survival and thus more sensitive to MEK inhibitors. This evidence concerns the gene MAP2K7 and cancer.